C
Congenica
Clinical genomics analytics platform
About Congenica
Congenica is a digital health startup that specializes in the analysis and interpretation of genomic data. The company's primary focus is on precision medicine, which involves tailoring medical treatments to individual patients based on their genetic makeup. By leveraging state-of-the-art technology, automation, and artificial intelligence, Congenica's platform can be used in various areas of human disease where genomic information is crucial for actionable insights.
Read full description
The company's business model revolves around providing automated analysis, diagnosis, and treatment solutions to healthcare providers and patients worldwide. This helps to reduce the burden on healthcare systems and streamline the decision-making process. Congenica's software is CE-IVD approved, meaning it meets the European Union's standards for in-vitro diagnostic medical devices. This ensures that the platform provides accurate and secure analysis to support clinical decisions with the highest degree of confidence.
Congenica serves a diverse range of clients, including the National Health Service (NHS) Genomic Medicine Service, international laboratories, academic medical centers, hospitals, and biopharmaceutical companies. The company operates in the global healthcare market, with a particular emphasis on oncology, as evidenced by their recent contract to develop a Next Generation Sequencing (NGS) analysis workflow in this field.
The company generates revenue through its Software as a Service (SaaS) model, offering its genomic data analysis platform either on-premise or via the cloud. This flexibility allows Congenica to cater to the varying needs of its customers.
At a glance
- Status
- Acquired
- Founded
- 2014
- Headquarters
- Hinxton, United Kingdom
- Employees
- 30
- Open positions
- 2
- Dealroom signal
- 63.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Analytics, Biotechnology, rio AI physician support, uk rio, DNA, Genetics and genomics, Precision Medicine, Health Diagnostics, Spinout, Genome Engineering
- Business model
- SaaS
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Sep 2025 | $0 | — | SeqOne | ↗ |
| LATE VCOther financing | Mar 2021 | $0 | — | QVentures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Congenica is 12K monthly website visits, up 361.5% over the last three months. Congenica's team declined 3.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Cambridge Innovation Capital
Amadeus Capital Partners
Future Planet Capital- HCHealthlink Capital
Parkwalk Advisors
Series B and later4 investors entered at this stage
Tencent
Legal & General
Legal & General Capital
QVentures
Other known investors3 additional known investors
SeqOne
University of Cambridge
Wellcome Trust Sanger Institute
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Congenica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Congenica’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.